cabamiquine

Cabamiquine (M5717) is a synthetic small molecule antimalarial drug under clinical development. It acts as a potent inhibitor of *Plasmodium* translation elongation factor 2 (eEF2), thereby blocking parasite protein synthesis and arresting growth across multiple stages of the malaria parasite life cycle—including blood stage, liver stage, and gametocytes. This multistage activity gives it potential for both treatment and transmission-blocking or prophylactic use. Cabamiquine has a long plasma half-life in humans (over 150 hours), which supports its use in single-dose regimens or combination therapies. Resistance can develop if used as monotherapy; therefore, it is being developed primarily in combination with other antimalarials such as pyronaridine to reduce resistance risk and improve efficacy[1][3][4][5][8].

Other names

cabamiquineM5717M-5717M 5717DDD107498DDD-107498DDD 107498DDD498DDD-498DDD 498